Article

Influenza vaccination coverage and related factors among Spanish patients with chronic obstructive pulmonary disease

Unidad de Docencia e Investigación en Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avda de Atenas s/n, Alcorcón 28402, Spain.
Vaccine (Impact Factor: 3.49). 06/2005; 23(28):3679-86. DOI: 10.1016/j.vaccine.2005.02.007
Source: PubMed

ABSTRACT This study sought: to describe influenza vaccination coverages among COPD patients treated in a primary-care setting; and to analyse the factors linked to compliance with vaccination recommendations. This was a descriptive study in a primary-care (PC) setting. Each of the 2422 randomly selected medical practitioners included in the study was required to recruit five COPD patients. Information was drawn from patients' clinical histories and personal interviews. As the dependent variable, we took the answer (yes or no) to the question, "did you have an influenza vaccination in the most recent campaign?"; and as independent variables, we analysed socio-demographic data, health-status related variables, lifestyles and history of pneumococcal vaccination. A total of 10,711 patients were enrolled 87.2% reported having been vaccinated in the most recent campaign. In conclusion, Spanish COPD patients treated in a primary-care setting can be said to enjoy good vaccine coverages against the influenza virus. More frequent contact with the general practitioner and a history of pneumococcal vaccination increase the likelihood of being vaccinated considerably, and measures should be implemented with the aim of improving coverages among younger subjects and those who lead less healthy lifestyles.

0 Followers
 · 
87 Views
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in adults. Pneumococcal vaccination is recommended to persons suffering COPD. This study aimed at describing pneumococcal vaccination coverages in patients with COPD and analyzing the factors associated with such vaccination. This was designed as a descriptive study conducted in the primary-care setting. Each of the 2422 medical practitioners included in the study had to enroll five COPD patients. As the dependent variable, we took the answer to the question, "Have you ever been given a pneumococcal vaccine shot at some time in your life?". As independent variables, we analyzed sociodemographic, health-status and lifestyle variables, along with history of influenza vaccination. A total of 10,711 patients were enrolled and, 32.5% (95% CI 31.6-33.4) of participants reported receiving pneumococcal vaccination. Female gender, higher age and more advanced COPD stage were the variables associated with a higher likelihood of being vaccinated. History of influenza vaccination in the most recent campaign was also associated with pneumococcal vaccination. Pneumococcal vaccination coverages among Spanish COPD patients are low and strategies to improve them must be implemented as a matter of urgency.
    Human vaccines 05/2006; 2(3):99-104. DOI:10.4161/hv.2756 · 3.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Based on data drawn from the 1993 and 2003 National Health Surveys (NHS), we sought to: estimate influenza vaccination coverages among Spanish cardiovascular disease (CVD) sufferers; study which variables were associated with the likelihood of being vaccinated; analyze the time-trend in coverage for the period 1993-2003. For study purposes, a CVD sufferer was defined as any adult who reported suffering from high blood pressure and/or heart disease. The proportion of vaccinated adult CVD sufferers in 1993 and 2003 totalled 39.96% and 51.73%, respectively. The following variables increased the likelihood of being vaccinated: higher age; male gender; presence of respiratory chronic diseases; non-smoker status. Coverages for CVD sufferers had improved significantly from 1993 to 2003 but still remain below desirable levels. The improvement over time is mainly due to the subgroup aged >64 years. Strategies must be implemented to improve the use of influenza vaccine among CVD sufferers in Spain in general, and among the younger age-groups in particular.
    Vaccine 06/2006; 24(23):5073-82. DOI:10.1016/j.vaccine.2006.03.036 · 3.49 Impact Factor
Show more